Dyne Therapeutics Inc

NASDAQ:DYN  
14.91
+0.02 (+0.13%)
Other Pre-Announcement

Dyne Therapeutics Inc Highlights Preclinical Data And Clinical Development Plans For DMD And DM1 Programs At Inaugural Research And Development Day

Published: 10/13/2021 12:05 GMT
Dyne Therapeutics Inc (DYN) - Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for Dmd and Dm1 Programs at Inaugural Research and Development Day.
Dyne Therapeutics Inc - Ind Submissions Anticipated for Dyne-251 in Dmd During Q4 of 2021 and for Dyne-101 in Dm1 During Q1 of 2022.
Dyne Therapeutics Inc - Expects to Submit an Ind for Dyne-301 in Facioscapulohumeral Muscular Dystrophy (fshd) in Second Half of 2022.